Please wait while the formulary information is being retrieved.
VPRIV (VELAGLUCERASE ALFA)
- Gaucher's disease
400 unit intravenous solution
- Infuse 15 unit/kg over 60 minute(s) by intravenous route every 2 weeks
Gaucher's disease
- Infuse 60 unit/kg over 60 minute(s) by intravenous route every 2 weeks
- Infuse 60 unit/kg over 60 minute(s) by intravenous route every 14 days
- Infuse 15 unit/kg over 60 minute(s) by intravenous route every 2 weeks
- Infuse 15 unit/kg over 60 minute(s) by intravenous route every 14 days
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
VPRIV (VELAGLUCERASE ALFA)
- Gaucher's disease
- Hypersensitivity drug reaction
- Acute abdominal pain
- Arthralgias
- Back pain
- Dizziness
- Fatigue
- Fever
- General weakness
- Headache disorder
- Nausea
- Prolonged activated partial thromboplastin time
More Frequent
Severe
Less Severe
- Urticaria
- Bone pain
- Skin rash
- Tachycardia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Hypertension
- Hypotension
- Vomiting
Less Severe
- Flushing
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Velaglucerase alfa
Safety and efficacy not established age < 4 years.
- 1 Day – 4 Years
- Safety and efficacy not established age < 4 years.
Velaglucerase Alfa
- Severity Level:
2
- Additional Notes: Available human data show no increased risk for major birth defects.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Velaglucerase Alfa
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Gaucher's disease | |
| E75.22 | Gaucher disease |
| 0-9 | A-Z |
|---|---|
| E75.22 | Gaucher disease |
Formulary Reference Tool